UBS O'Connor »

Black Diamond Therapeutics shares owned by UBS O'Connor

Quarter-by-quarter ownership of Black Diamond Therapeutics (BDTX) shares owned by UBS O'Connor from 13F filings

Historical chart of UBS O'Connor investment in Black Diamond Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Black Diamond Therapeutics held by UBS O'Connor consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Black Diamond Therapeutics by UBS O'Connor

Quarter filed Position value Share count Share price at filing
2024-03-31 $1.3M 257k 5.07

More positions owned by UBS O'Connor

Spirit Air Note1 (Principal)
Peloton In Note2 (Principal)
Ryanair Ho Spons (RYAAY)
Revance Th Note1 (Principal)
Occidental Petroleum Corporation (OXY)
Okta Cla (OKTA)
NVIDIA Corporation (NVDA)
New Provid Class (NPAB)
Acorda The Note6 (Principal)
Bandwidth Note0 (Principal)
Screaming Class
Norfolk Southern (NSC)
Pentair Pl SHS (PNR)
Broadcom (AVGO)
Autoliv (ALV)

View all positions for UBS O'Connor

Top funds holding Black Diamond Therapeutics

T. Rowe Price Investment Management
Bellevue Group
NEA Management Company
BlackRock
Vanguard Group
Vestal Point Capital
Tang Capital Management
Millennium Management
Artal Group
Geode Capital Management
T. Rowe Price Associates
Invesco
Kennedy Capital Management
State Street Corporation
Stempoint Capital

View all funds holding Black Diamond Therapeutics